Home
Resources
Publications
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease

Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease

Mattia Cocco, Carolina Pellegrini, Helios Martínez-Banaclocha, Marta Giorgis, Elisabetta Marini, Annalisa Costale, Gianluca Miglio, Matteo Fornai, Luca Antonioli, Gloria López-Castejón, Ana Tapia-Abellán, etc.

J Med Chem. 2017 May 11;60(9):3656-3671.

PMID: 28410442

Abstract:

Pharmacological inhibition of NLRP3 inflammasome activation may offer a new option in the treatment of inflammatory bowel disease. In this work, we report the design, synthesis, and biological screening of a series of acrylate derivatives as NLRP3 inhibitors. The in vitro determination of reactivity, cytotoxicity, NLRP3 ATPase inhibition, and antipyroptotic properties allowed the selection of 11 (INF39), a nontoxic, irreversible NLRP3 inhibitor able to decrease interleukin-1β release from macrophages. Bioluminescence resonance energy transfer experiments proved that this compound was able to directly interfere with NLRP3 activation in cells. In vivo studies confirmed the ability of the selected lead to alleviate the effects of colitis induced by 2,4-dinitrobenzenesulfonic acid in rats after oral administration.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP866028264	INF39		866028-26-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: